In a mouse model of breast cancer, treatment with neutralizing antibodies against MCP-1 enhanced survival and decreased metastasis [22], suggesting that targeting of this pathway in human cancer will likely prove beneficial. This evidence concerns the gene CCL2 and breast carcinoma.